Therapy with esophageal protector in the management of GERD with extraesophageal symptoms
DOI: 10.32364/2587-6821-2022-6-5-237-243
I.V. Lapteva1, M.M. Fedorin2, K.I. Nesterova2, M.A. Livzan2, S.I. Mozgovoy2
1City Hospital No. 3, Omsk, Russian Federation
2Omsk State Medical University, Omsk, Russian Federation
Gastroesophageal reflux disease (GERD) is one of the most common reasons for referral to a physician. Gastroesophageal reflux-associated extraesophageal symptoms occur in every third patient with GERD. Diagnostic difficulties and the prescription of effective treatment to rapid resolve GERD extraesophageal symptoms are still important issues when managing these patients. This paper summarizes data on the prevalence and pattern of GERD extraesophageal symptoms, as well as the efficacy and safety of therapies for GERD with extraesophageal symptoms with esophageal protector. The esophageal protector mechanically protects the laryngeal and esophageal mucosa, improving the recovery of its molecular cellular structure and normalizing barrier function, and reduces extraesophageal symptoms of GERD. The action of the esophageal protector is realized via its ability to envelop and protect the oropharynx and esophagus from the harmful effects of acid or biliary reflux, hydrate m ucosa, and provide direct healing action. This results in a more rapid and complete recovery of the esophageal and laryngeal epithelium.
Keywords: gastroesophageal reflux disease, extraesophageal symptoms, laryngopharyngeal reflux, esophageal protector, hyaluronic acid, chondroitin sulfate.
For citation: Lapteva I.V., Fedorin M.M., Nesterova K.I. et al. Therapy with esophageal protector in the management of GERD with extraesophageal symptoms. Russian Medical Inquiry. 2022;6(5):237–243 (in Russ.). DOI: 10.32364/2587-6821-2022-6-5-237-243.
About the authors:
Irina V. Lapteva — C. Sc. (Med.), Head of the Therapeutic Department No. 1, Head of the Gastroenterological Center, City Hospital No. 3; 19, Energetikov str., Omsk, 644029, Russian Federation.
Maksim M. Fedorin — resident of the Department of Faculty Therapy and Gastroenterology, Omsk State Medical University; 12, Lenin str., Omsk, 644099, Russian Federation; ORCID iD 0000-0002-0238-4664.
Klimentina I. Nesterova — Dr. Sc. (Med.), Associate Professor, professor of the Department of Otorhinolaryngology, Omsk State Medical University; 12, Lenin str., Omsk, 644099, Russian Federation; ORCID iD 0000-0002-9793-7179.
Maria A. Livzan — Dr. Sc. (Med.), Professor, Corresponding Member of the RAS, Head of the Department of Faculty Therapy and Gastroenterology, Chancellor Omsk State Medical University; 12, Lenin str., Omsk, 644099, Russian Federation; ORCID iD 0000-0002-6581-7017.
Sergey I. Mozgovoy — Dr. Sc. (Med.), Associate Professor, professor of the Department of Pathological Anatomy, Omsk State Medical University; 12, Lenin str., Omsk, 644099, Russian Federation; ORCID iD 0000-0002-6733-5572.
Contact information: Maksim M. Fedorin, e-mail: mail.maxim.f@gmail.com.
Financial Disclosure: no authors have a financial or property interest in any material or method mentioned.
There is no conflict of interests.
Received 22.03.2022.
Revised 14.04.2022.
Accepted 13.05.2022.
References
1. Chatila A.T., Nguyen M.T.T., Krill T. et al. Natural history, pathophysiology and evaluation of gastroesophageal reflux disease. Dis Mon. 2020;66(1):100848. DOI: 10.1016/j.disamonth.2019.02.001.
2. El-Serag H.B., Sweet S., Winchester C.C., Dent J. Update on the epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut. 2014;63(6):871–880. DOI: 10.1136/gutjnl-2012-304269.
3. Ивашкин В.Т., Маев И.В., Трухманов А.С. и др. Рекомендации Российской гастроэнтерологической ассоциации по диагностике и лечению гастроэзофагеальной рефлюксной болезни. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2020;30(4):70–97. DOI: 10.22416/1382-4376-2020-30-4-70-97. [Ivashkin V.T., Maev I.V., Trukhmanov A.S. et al. Recommendations of the Russian Gastroenterological Association in Diagnosis and Treatment of Gastroesophageal Reflux Disease. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2020;30(4):70–97 (in Russ.)]. DOI: 10.22416/1382-4376-2020-30-4-70-97.
4. Vakil N., van Zanten S.V., Kahrilas P. et al. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol. 2006;101(8):1900–1920; quiz 1943. DOI: 10.1111/j.1572-0241.2006.00630.x.
5. Jaspersen D., Kulig M., Labenz J. et al. Prevalence of extra-oesophageal manifestations in gastro-oesophageal reflux disease: an analysis based on the ProGERD Study. Aliment Pharmacol Ther. 2003;17(12):1515–1520. DOI: 10.1046/j.1365-2036.2003.01606.x.
6. Маев И.В., Андреев Д.Н., Юренев Г.Л. и др. Ларингофарингеальный рефлюкс. М.: Рекламное агентство «Ре Медиа»; 2022. [Maev I.V., Andreev D.N., Yurenev G.L. et al. Laryngopharyngeal reflux. M.: Re Media Advertising Agency; 2022 (in Russ.)].
7. Locke G.R. 3rd, Talley N.J., Fett S.L. et al. Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. Gastroenterology. 1997;112(5):1448–1456. DOI: 10.1016/s0016-5085(97)70025-8.
8. Broers C., Tack J., Pauwels A. Review article: gastro-oesophageal reflux disease in asthma and chronic obstructive pulmonary disease. Aliment Pharmacol Ther. 2018;47(2):176–191. DOI: 10.1111/apt.14416.
9. Belafsky P.C., Postma G.N., Koufman J.A. The validity and reliability of the reflux finding score (RFS). Laryngoscope. 2001;111(8):1313–1317. DOI: 10.1097/00005537-200108000-00001.
10. Ates F., Vaezi M.F. Approach to the patient with presumed extraoesophageal GERD. Best Pract Res Clin Gastroenterol. 2013;27(3):415–431. DOI: 10.1016/j.bpg.2013.06.009.
11. Blevins C.H., Iyer P.G., Vela M.F., Katzka D.A. The esophageal epithelial barrier in health and disease. Clin Gastroenterol Hepatol. 2018;16(5):608–617. DOI: 10.1016/j.cgh.2017.06.035.
12. Rieder F., Biancani P., Harnett K. et al. Inflammatory mediators in gastroesophageal reflux disease: impact on esophageal motility, fibrosis, and carcinogenesis. Am J Physiol Gastrointest Liver Physiol. 2010;298(5):G571–G581. DOI: 10.1152/ajpgi.00454.2009.
13. Tobey N.A., Hosseini S.S., Argote C.M. et al. Dilated intercellular spaces and shunt permeability in nonerosive acid-damaged esophageal epithelium. Am J Gastroenterol. 2004;99(1):13–22. DOI: 10.1046/j.1572-0241.2003.04018.x.
14. Durazzo M., Lupi G., Cicerchia F. et al. Extra-esophageal presentation of gastroesophageal reflux disease: 2020 Update. J Clin Med. 2020;9(8):2559. DOI: 10.3390/jcm9082559.
15. Irwin R.S., French C.L., Chang A.B. et al. Classification of Cough as a Symptom in Adults and Management Algorithms: CHEST Guideline and Expert Panel Report. Chest. 2018;153(1):196–209. DOI: 10.1016/j.chest.2017.10.016.
16. Zhang Z., Bao Y.Y., Zhou S.H. Pump proton and laryngeal H+/K+ ATPases. Int J Gen Med. 2020;13:1509–1514. DOI: 10.2147/IJGM.S284952.
17. Алексеенко С.А., Багдасарян А.А., Бакулин И.Г. и др. Краткие алгоритмы ведения пациентов на этапе оказания первичной медико-санитарной помощи. М.: Видокс; 2019. [Alekseenko S.A., Bagdasaryan A.A., Bakulin I.G. et al. Brief Algorithms for Studying Patients in Standard Health Care Practice. M.: Vidoks; 2019 (in Russ.)].
18. Shin J.M., Cho Y.M., Sachs G. Chemistry of covalent inhibition of the gastric (H+, K+)-ATPase by proton pump inhibitors. J Am Chem Soc. 2004;126(25):7800–7811. DOI: 10.1021/ja049607w.
19. Zhang J.X., Ji M.Y., Song J. et al. Proton pump inhibitor for non-erosive reflux disease: a meta-analysis. World J Gastroenterol. 2013;19(45):8408–8419. DOI: 10.3748/wjg.v19.i45.8408.
20. Chang A.B., Lasserson T.J., Kiljander T.O. et al. Systematic review and meta-analysis of randomised controlled trials of gastro-oesophageal reflux interventions for chronic cough associated with gastro-oesophageal reflux. BMJ. 2006;332(7532):11–17. DOI: 10.1136/bmj.38677.559005.55.
21. Shaheen N.J., Crockett S.D., Bright S.D. et al. Randomised clinical trial: high-dose acid suppression for chronic cough — a double-blind, placebo-controlled study. Aliment Pharmacol Ther. 2011;33(2):225–234. DOI: 10.1111/j.1365-2036.2010.04511.x.
22. Harding S.M., Richter J.E., Guzzo M.R. et al. Asthma and gastroesophageal reflux: acid suppressive therapy improves asthma outcome. Am J Med. 1996;100(4):395–405. DOI: 10.1016/S0002-9343(97)89514-9.
23. Gibson P.G., Henry R.L., Coughlan J.L. Gastro-oesophageal reflux treatment for asthma in adults and children. Cochrane Database Syst Rev. 2003;(2):CD001496. DOI: 10.1002/14651858.CD001496.
24. Chan W.W., Chiou E., Obstein K.L. et al. The efficacy of proton pump inhibitors for the treatment of asthma in adults: a meta-analysis. Arch Intern Med. 2011;171(7):620–629. DOI: 10.1001/archinternmed.2011.116.
25. Wei C. A meta-analysis for the role of proton pump inhibitor therapy in patients with laryngopharyngeal reflux. Eur Arch Otorhinolaryngol. 2016;273(11):3795–3801. DOI: 10.1007/s00405-016-4142-y.
26. Qadeer M.A., Phillips C.O., Lopez A.R. et al. Proton pump inhibitor therapy for suspected GERD-related chronic laryngitis: a meta-analysis of randomized controlled trials. Am J Gastroenterol. 2006;101(11):2646–2654. DOI: 10.1111/j.1572-0241.2006.00844.x.
27. Marshall T.A. Dietary assessment and counseling for dental erosion. J Am Dent Assoc. 2018;149(2):148–152. DOI: 10.1016/j.adaj.2017.11.006.
28. Kahrilas P.J., Altman K.W., Chang A.B. et al. Chronic Cough Due to Gastroesophageal Reflux in Adults: CHEST Guideline and Expert Panel Report. Chest. 2016;150(6):1341–1360. DOI: 10.1016/j.chest.2016.08.1458.
29. Sidwa F., Moore A.L., Alligood E., Fisichella P.M. Surgical treatment of extraesophageal manifestations of gastroesophageal reflux disease. World J Surg. 2017;41(10):2566–2571. DOI: 10.1007/s00268-017-4058-8.
30. Krill J.T., Naik R.D., Higginbotham T. et al. Association between response to acid-suppression therapy and efficacy of antireflux surgery in patients with extraesophageal reflux. Clin Gastroenterol Hepatol. 2017;15(5):675–681. DOI: 10.1016/j.cgh.2016.10.031.
31. Klaus A., Swain J.M., Hinder R.A. Laparoscopic antireflux surgery for supraesophageal complications of gastroesophageal reflux disease. Am J Med. 2001;111 Suppl 8A:202S–206S. DOI: 10.1016/s0002-9343(01)00831-2.
32. Lugaresi M., Aramini B., Daddi N. et al. Effectiveness of antireflux surgery for the cure of chronic cough associated with gastroesophageal reflux disease. World J Surg. 2015;39(1):208–215. DOI: 10.1007/s00268-014-2769-7.
33. Маев И.В., Андреев Д.Н., Кучерявый Ю.А., Шабуров Р.И. Современные достижения в лечении гастроэзофагеальной рефлюксной болезни: фокус на эзофагопротекцию. Терапевтический архив. 2019;91(8):4–11. DOI: 10.26442/00403660.2019.08.00038. [Maev I.V., Andreev D.N., Kucheryavyy Yu.A., Shaburov R.I. Current advances in the treatment of gastroesophageal reflux disease: a focus on esophageal protection. Therapeutic Archive. 2019;91(8):4–11 (in Russ.)]. DOI: 10.26442/00403660.2019.08.000387.
34. Sifrim D., Fornari F. Esophageal impedance-pH monitoring. Dig Liver Dis. 2008;40(3):161–166. DOI: 10.1016/j.dld.2007.10.023.
35. Lee J.S., Jung A.R., Park J.M. et al. Comparison of characteristics according to reflux type in patients with laryngopharyngeal reflux. Clin Exp Otorhinolaryngol. 2018;11(2):141–145. DOI: 10.21053/ceo.2017.00577.
36. Hopwood D., Bateson M.C., Milne G., Bouchier I.A. Effects of bile acids and hydrogen ion on the fine structure of oesophageal epithelium. Gut. 1981;22(4):306–311. DOI: 10.1136/gut.22.4.306.
37. Dixon M.F., Neville P.M., Mapstone N.P. et al. Bile reflux gastritis and Barrett’s oesophagus: further evidence of a role for duodenogastro-oesophageal reflux? Gut. 2001;49(3):359–363. DOI: 10.1136/gut.49.3.359.
38. Ливзан М.А., Кононов А.В. Клинические и фармакоэкономические аспекты антисекреторной терапии гастроэзофагеальной рефлюксной болезни. Экспериментальная и клиническая гастроэнтерология. 2004;4:55–61. [Livzan M.A., Kononov A.V. Clinical and pharmacoeconomic aspects of the antisecretory therapy of gastroesophageal refluxed disease. Experimental and clinical gastroenterology journal. 2004;4:55–60 (in Russ.)].
39. Kwiatek M.A., Roman S., Fareeduddin A. et al. An alginate-antacid formulation (Gaviscon Double Action Liquid) can eliminate or displace the postprandial ‘acid pocket’ in symptomatic GERD patients. Aliment Pharmacol Ther. 2011;34(1):59–66. DOI: 10.1111/j.1365-2036.2011.04678.x.
40. Lechien J.R., Bobin F., Muls V. et al. Gastroesophageal reflux in laryngopharyngeal reflux patients: Clinical features and therapeutic response. Laryngoscope. 2020;130(8):E479–E489. DOI: 10.1002/lary.28482.
41. Lechien J.R., Mouawad F., Barillari M.R. et al. Treatment of laryngopharyngeal reflux disease: A systematic review. World J Clin Cases. 2019;7(19):2995–3011. DOI: 10.12998/wjcc.v7.i19.2995.
42. Матошина И.В., Ливзан М.А., Федорин М.М., Лаптева И.В. Клинически значимые стигмы выраженности ГЭРБ и диссоциация со степенью повреждения слизистой пищевода — обязательность эзофагопротекции? Экспериментальная и клиническая гастроэнтерология. 2021;190(6):5–11. DOI: 10.31146/1682-8658-ecg-190-6-5-11. [Matoshina I V., Livzan M.A., Fedorin M.M., Lapteva I.V. Clinically signifi cant stigmas of the severity of GERD and dissociation with the degree of damage to the esophageal mucosa — the obligatory esophagoprotection? Experimental and clinical gastroenterology journal. 2021;190(6):5–11 (in Russ.)]. DOI: 10.31146/1682-8658-ecg-190-6-5-11.
43. Savarino E., Zentilin P., Marabotto E. et al. Drugs for improving esophageal mucosa defense: where are we now and where are we going? Ann Gastroenterol. 2017;30(6):585–591. DOI: 10.20524/aog.2017.0187.
44. Gaffney J., Matou-Nasri S., Grau-Olivares M., Slevin M. Therapeutic applications of hyaluronan. Mol Biosyst. 2010;6(3):437–443. DOI: 10.1039/b910552m.
45. Volpi N., Schiller J., Stern R., Soltés L. Role, metabolism, chemical modifications and applications of hyaluronan. Curr Med Chem. 2009;16(14):1718–1745. DOI: 10.2174/092986709788186138.
46. Kim Y., Kessler S.P., Obery D.R. et al. Hyaluronan 35kDa treatment protects mice from Citrobacter rodentium infection and induces epithelial tight junction protein ZO-1 in vivo. Matrix Biol. 2017;62:28–39. DOI: 10.1016/j.matbio.2016.11.001.
47. Lauder R.M. Chondroitin sulphate: a complex molecule with potential impacts on a wide range of biological systems. Complement Ther Med. 2009;17(1):56–62. DOI: 10.1016/j.ctim.2008.08.004.
48. Volpi N. Anti-inflammatory activity of chondroitin sulphate: new functions from an old natural macromolecule. Inflammopharmacology. 2011;19(6):299–306. DOI: 10.1007/s10787-011-0098-0.
49. Du Souich P., García A.G., Vergés J., Montell E. Immunomodulatory and anti-inflammatory effects of chondroitin sulphate. J Cell Mol Med. 2009;13(8A):1451–1463. DOI: 10.1111/j.1582-4934.2009.00826.x.
50. Devi D., Sandhya P., Hari B.N. et al. Poloxamer: A novel functional molecule for drug delivery and gene therapy. J Pharm Sci Res. 2013;5(8):159–165.
51. Матошина И.В., Федорин М.М., Ливзан М.А., Мозговой C.И. Резистентность слизистой оболочки пищевода у больных ГЭРБ: диалог клинициста и морфолога. Эффективная фармакотерапия. 2021;17(4):34–39. DOI: 10.33978/2307-3586-2021-17-4-34-39. [Matoshina I.V., Fedorin M.M., Livzan M.A., Mozgovoy S.I. Resistance of the Esophageal Mucosa in Patients with GERD: the Dialogue Between Clinician and Pathologist. Effektivnaya farmakoterapiya. 2021;17(4):34–39 (in Russ.)]. DOI: 10.33978/2307-3586-2021-17-4-34-39.
52. Palmieri B., Merighi A., Corbascio D. et al. Fixed combination of hyaluronic acid and chondroitin-sulphate oral formulation in a randomized double blind, placebo controlled study for the treatment of symptoms in patients with non-erosive gastroesophageal reflux. Eur Rev Med Pharmacol Sci. 2013;17(24):3272–3278. PMID: 24379055.
53. Savarino V., Pace F., Scarpignato C.; Esoxx Study Group. Randomised clinical trial: mucosal protection combined with acid suppression in the treatment of non-erosive reflux disease — efficacy of Esoxx, a hyaluronic acid-chondroitin sulphate based bioadhesive formulation. Aliment Pharmacol Ther. 2017;45(5):631–642. DOI: 10.1111/apt.13914.
54. Матошина И.В., Ливзан М.А., Федорин М.М., Лаптева И.В. Эффективность комбинированной терапии больных эрозивной гастроэзофагеальной рефлюксной болезнью. РМЖ. Медицинское обозрение. 2021;5(6):366–372. DOI: 10.32364/2587-6821-2021-5-6-366-372. [Matoshina I.V., Livzan M.A., Fedorin M.M., Lapteva I.V. Efficacy of combined therapy in patients with erosive gastroesophageal reflux disease. Russian Medical Inquiry. 2021;5(6):366–372 (in Russ.)]. DOI: 10.32364/2587-6821-2021-5-6-366-372.
55. Матошина И.В., Мозговой С.И., Ливзан М.А., Федорин М.М. Новые возможности терапии эрозивной формы гастроэзофагеальной рефлюксной болезни: собственные данные. Современные проблемы науки и образования. 2021;5:86. DOI: 10.17513/spno.31128. [Matoshina I.V., Mozgovoy S.I., Livzan M.A., Fedorin M.M. New therapy options for erosive gastroesophageal reflux disease: own data. Sovremennyye problemy nauki i obrazovaniya. 2021;(5):86 (in Russ.)]. DOI: 10.17513/spno.31128.
56. Chmielecka-Rutkowska J., Tomasik B., Pietruszewska W. The role of oral formulation of hyaluronic acid and chondroitin sulphate for the treatment of the patients with laryngopharyngeal reflux. Otolaryngol Pol. 2019;73(6):38–49. DOI: 10.5604/01.3001.0013.5776.
2. El-Serag H.B., Sweet S., Winchester C.C., Dent J. Update on the epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut. 2014;63(6):871–880. DOI: 10.1136/gutjnl-2012-304269.
3. Ивашкин В.Т., Маев И.В., Трухманов А.С. и др. Рекомендации Российской гастроэнтерологической ассоциации по диагностике и лечению гастроэзофагеальной рефлюксной болезни. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2020;30(4):70–97. DOI: 10.22416/1382-4376-2020-30-4-70-97. [Ivashkin V.T., Maev I.V., Trukhmanov A.S. et al. Recommendations of the Russian Gastroenterological Association in Diagnosis and Treatment of Gastroesophageal Reflux Disease. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2020;30(4):70–97 (in Russ.)]. DOI: 10.22416/1382-4376-2020-30-4-70-97.
4. Vakil N., van Zanten S.V., Kahrilas P. et al. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol. 2006;101(8):1900–1920; quiz 1943. DOI: 10.1111/j.1572-0241.2006.00630.x.
5. Jaspersen D., Kulig M., Labenz J. et al. Prevalence of extra-oesophageal manifestations in gastro-oesophageal reflux disease: an analysis based on the ProGERD Study. Aliment Pharmacol Ther. 2003;17(12):1515–1520. DOI: 10.1046/j.1365-2036.2003.01606.x.
6. Маев И.В., Андреев Д.Н., Юренев Г.Л. и др. Ларингофарингеальный рефлюкс. М.: Рекламное агентство «Ре Медиа»; 2022. [Maev I.V., Andreev D.N., Yurenev G.L. et al. Laryngopharyngeal reflux. M.: Re Media Advertising Agency; 2022 (in Russ.)].
7. Locke G.R. 3rd, Talley N.J., Fett S.L. et al. Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. Gastroenterology. 1997;112(5):1448–1456. DOI: 10.1016/s0016-5085(97)70025-8.
8. Broers C., Tack J., Pauwels A. Review article: gastro-oesophageal reflux disease in asthma and chronic obstructive pulmonary disease. Aliment Pharmacol Ther. 2018;47(2):176–191. DOI: 10.1111/apt.14416.
9. Belafsky P.C., Postma G.N., Koufman J.A. The validity and reliability of the reflux finding score (RFS). Laryngoscope. 2001;111(8):1313–1317. DOI: 10.1097/00005537-200108000-00001.
10. Ates F., Vaezi M.F. Approach to the patient with presumed extraoesophageal GERD. Best Pract Res Clin Gastroenterol. 2013;27(3):415–431. DOI: 10.1016/j.bpg.2013.06.009.
11. Blevins C.H., Iyer P.G., Vela M.F., Katzka D.A. The esophageal epithelial barrier in health and disease. Clin Gastroenterol Hepatol. 2018;16(5):608–617. DOI: 10.1016/j.cgh.2017.06.035.
12. Rieder F., Biancani P., Harnett K. et al. Inflammatory mediators in gastroesophageal reflux disease: impact on esophageal motility, fibrosis, and carcinogenesis. Am J Physiol Gastrointest Liver Physiol. 2010;298(5):G571–G581. DOI: 10.1152/ajpgi.00454.2009.
13. Tobey N.A., Hosseini S.S., Argote C.M. et al. Dilated intercellular spaces and shunt permeability in nonerosive acid-damaged esophageal epithelium. Am J Gastroenterol. 2004;99(1):13–22. DOI: 10.1046/j.1572-0241.2003.04018.x.
14. Durazzo M., Lupi G., Cicerchia F. et al. Extra-esophageal presentation of gastroesophageal reflux disease: 2020 Update. J Clin Med. 2020;9(8):2559. DOI: 10.3390/jcm9082559.
15. Irwin R.S., French C.L., Chang A.B. et al. Classification of Cough as a Symptom in Adults and Management Algorithms: CHEST Guideline and Expert Panel Report. Chest. 2018;153(1):196–209. DOI: 10.1016/j.chest.2017.10.016.
16. Zhang Z., Bao Y.Y., Zhou S.H. Pump proton and laryngeal H+/K+ ATPases. Int J Gen Med. 2020;13:1509–1514. DOI: 10.2147/IJGM.S284952.
17. Алексеенко С.А., Багдасарян А.А., Бакулин И.Г. и др. Краткие алгоритмы ведения пациентов на этапе оказания первичной медико-санитарной помощи. М.: Видокс; 2019. [Alekseenko S.A., Bagdasaryan A.A., Bakulin I.G. et al. Brief Algorithms for Studying Patients in Standard Health Care Practice. M.: Vidoks; 2019 (in Russ.)].
18. Shin J.M., Cho Y.M., Sachs G. Chemistry of covalent inhibition of the gastric (H+, K+)-ATPase by proton pump inhibitors. J Am Chem Soc. 2004;126(25):7800–7811. DOI: 10.1021/ja049607w.
19. Zhang J.X., Ji M.Y., Song J. et al. Proton pump inhibitor for non-erosive reflux disease: a meta-analysis. World J Gastroenterol. 2013;19(45):8408–8419. DOI: 10.3748/wjg.v19.i45.8408.
20. Chang A.B., Lasserson T.J., Kiljander T.O. et al. Systematic review and meta-analysis of randomised controlled trials of gastro-oesophageal reflux interventions for chronic cough associated with gastro-oesophageal reflux. BMJ. 2006;332(7532):11–17. DOI: 10.1136/bmj.38677.559005.55.
21. Shaheen N.J., Crockett S.D., Bright S.D. et al. Randomised clinical trial: high-dose acid suppression for chronic cough — a double-blind, placebo-controlled study. Aliment Pharmacol Ther. 2011;33(2):225–234. DOI: 10.1111/j.1365-2036.2010.04511.x.
22. Harding S.M., Richter J.E., Guzzo M.R. et al. Asthma and gastroesophageal reflux: acid suppressive therapy improves asthma outcome. Am J Med. 1996;100(4):395–405. DOI: 10.1016/S0002-9343(97)89514-9.
23. Gibson P.G., Henry R.L., Coughlan J.L. Gastro-oesophageal reflux treatment for asthma in adults and children. Cochrane Database Syst Rev. 2003;(2):CD001496. DOI: 10.1002/14651858.CD001496.
24. Chan W.W., Chiou E., Obstein K.L. et al. The efficacy of proton pump inhibitors for the treatment of asthma in adults: a meta-analysis. Arch Intern Med. 2011;171(7):620–629. DOI: 10.1001/archinternmed.2011.116.
25. Wei C. A meta-analysis for the role of proton pump inhibitor therapy in patients with laryngopharyngeal reflux. Eur Arch Otorhinolaryngol. 2016;273(11):3795–3801. DOI: 10.1007/s00405-016-4142-y.
26. Qadeer M.A., Phillips C.O., Lopez A.R. et al. Proton pump inhibitor therapy for suspected GERD-related chronic laryngitis: a meta-analysis of randomized controlled trials. Am J Gastroenterol. 2006;101(11):2646–2654. DOI: 10.1111/j.1572-0241.2006.00844.x.
27. Marshall T.A. Dietary assessment and counseling for dental erosion. J Am Dent Assoc. 2018;149(2):148–152. DOI: 10.1016/j.adaj.2017.11.006.
28. Kahrilas P.J., Altman K.W., Chang A.B. et al. Chronic Cough Due to Gastroesophageal Reflux in Adults: CHEST Guideline and Expert Panel Report. Chest. 2016;150(6):1341–1360. DOI: 10.1016/j.chest.2016.08.1458.
29. Sidwa F., Moore A.L., Alligood E., Fisichella P.M. Surgical treatment of extraesophageal manifestations of gastroesophageal reflux disease. World J Surg. 2017;41(10):2566–2571. DOI: 10.1007/s00268-017-4058-8.
30. Krill J.T., Naik R.D., Higginbotham T. et al. Association between response to acid-suppression therapy and efficacy of antireflux surgery in patients with extraesophageal reflux. Clin Gastroenterol Hepatol. 2017;15(5):675–681. DOI: 10.1016/j.cgh.2016.10.031.
31. Klaus A., Swain J.M., Hinder R.A. Laparoscopic antireflux surgery for supraesophageal complications of gastroesophageal reflux disease. Am J Med. 2001;111 Suppl 8A:202S–206S. DOI: 10.1016/s0002-9343(01)00831-2.
32. Lugaresi M., Aramini B., Daddi N. et al. Effectiveness of antireflux surgery for the cure of chronic cough associated with gastroesophageal reflux disease. World J Surg. 2015;39(1):208–215. DOI: 10.1007/s00268-014-2769-7.
33. Маев И.В., Андреев Д.Н., Кучерявый Ю.А., Шабуров Р.И. Современные достижения в лечении гастроэзофагеальной рефлюксной болезни: фокус на эзофагопротекцию. Терапевтический архив. 2019;91(8):4–11. DOI: 10.26442/00403660.2019.08.00038. [Maev I.V., Andreev D.N., Kucheryavyy Yu.A., Shaburov R.I. Current advances in the treatment of gastroesophageal reflux disease: a focus on esophageal protection. Therapeutic Archive. 2019;91(8):4–11 (in Russ.)]. DOI: 10.26442/00403660.2019.08.000387.
34. Sifrim D., Fornari F. Esophageal impedance-pH monitoring. Dig Liver Dis. 2008;40(3):161–166. DOI: 10.1016/j.dld.2007.10.023.
35. Lee J.S., Jung A.R., Park J.M. et al. Comparison of characteristics according to reflux type in patients with laryngopharyngeal reflux. Clin Exp Otorhinolaryngol. 2018;11(2):141–145. DOI: 10.21053/ceo.2017.00577.
36. Hopwood D., Bateson M.C., Milne G., Bouchier I.A. Effects of bile acids and hydrogen ion on the fine structure of oesophageal epithelium. Gut. 1981;22(4):306–311. DOI: 10.1136/gut.22.4.306.
37. Dixon M.F., Neville P.M., Mapstone N.P. et al. Bile reflux gastritis and Barrett’s oesophagus: further evidence of a role for duodenogastro-oesophageal reflux? Gut. 2001;49(3):359–363. DOI: 10.1136/gut.49.3.359.
38. Ливзан М.А., Кононов А.В. Клинические и фармакоэкономические аспекты антисекреторной терапии гастроэзофагеальной рефлюксной болезни. Экспериментальная и клиническая гастроэнтерология. 2004;4:55–61. [Livzan M.A., Kononov A.V. Clinical and pharmacoeconomic aspects of the antisecretory therapy of gastroesophageal refluxed disease. Experimental and clinical gastroenterology journal. 2004;4:55–60 (in Russ.)].
39. Kwiatek M.A., Roman S., Fareeduddin A. et al. An alginate-antacid formulation (Gaviscon Double Action Liquid) can eliminate or displace the postprandial ‘acid pocket’ in symptomatic GERD patients. Aliment Pharmacol Ther. 2011;34(1):59–66. DOI: 10.1111/j.1365-2036.2011.04678.x.
40. Lechien J.R., Bobin F., Muls V. et al. Gastroesophageal reflux in laryngopharyngeal reflux patients: Clinical features and therapeutic response. Laryngoscope. 2020;130(8):E479–E489. DOI: 10.1002/lary.28482.
41. Lechien J.R., Mouawad F., Barillari M.R. et al. Treatment of laryngopharyngeal reflux disease: A systematic review. World J Clin Cases. 2019;7(19):2995–3011. DOI: 10.12998/wjcc.v7.i19.2995.
42. Матошина И.В., Ливзан М.А., Федорин М.М., Лаптева И.В. Клинически значимые стигмы выраженности ГЭРБ и диссоциация со степенью повреждения слизистой пищевода — обязательность эзофагопротекции? Экспериментальная и клиническая гастроэнтерология. 2021;190(6):5–11. DOI: 10.31146/1682-8658-ecg-190-6-5-11. [Matoshina I V., Livzan M.A., Fedorin M.M., Lapteva I.V. Clinically signifi cant stigmas of the severity of GERD and dissociation with the degree of damage to the esophageal mucosa — the obligatory esophagoprotection? Experimental and clinical gastroenterology journal. 2021;190(6):5–11 (in Russ.)]. DOI: 10.31146/1682-8658-ecg-190-6-5-11.
43. Savarino E., Zentilin P., Marabotto E. et al. Drugs for improving esophageal mucosa defense: where are we now and where are we going? Ann Gastroenterol. 2017;30(6):585–591. DOI: 10.20524/aog.2017.0187.
44. Gaffney J., Matou-Nasri S., Grau-Olivares M., Slevin M. Therapeutic applications of hyaluronan. Mol Biosyst. 2010;6(3):437–443. DOI: 10.1039/b910552m.
45. Volpi N., Schiller J., Stern R., Soltés L. Role, metabolism, chemical modifications and applications of hyaluronan. Curr Med Chem. 2009;16(14):1718–1745. DOI: 10.2174/092986709788186138.
46. Kim Y., Kessler S.P., Obery D.R. et al. Hyaluronan 35kDa treatment protects mice from Citrobacter rodentium infection and induces epithelial tight junction protein ZO-1 in vivo. Matrix Biol. 2017;62:28–39. DOI: 10.1016/j.matbio.2016.11.001.
47. Lauder R.M. Chondroitin sulphate: a complex molecule with potential impacts on a wide range of biological systems. Complement Ther Med. 2009;17(1):56–62. DOI: 10.1016/j.ctim.2008.08.004.
48. Volpi N. Anti-inflammatory activity of chondroitin sulphate: new functions from an old natural macromolecule. Inflammopharmacology. 2011;19(6):299–306. DOI: 10.1007/s10787-011-0098-0.
49. Du Souich P., García A.G., Vergés J., Montell E. Immunomodulatory and anti-inflammatory effects of chondroitin sulphate. J Cell Mol Med. 2009;13(8A):1451–1463. DOI: 10.1111/j.1582-4934.2009.00826.x.
50. Devi D., Sandhya P., Hari B.N. et al. Poloxamer: A novel functional molecule for drug delivery and gene therapy. J Pharm Sci Res. 2013;5(8):159–165.
51. Матошина И.В., Федорин М.М., Ливзан М.А., Мозговой C.И. Резистентность слизистой оболочки пищевода у больных ГЭРБ: диалог клинициста и морфолога. Эффективная фармакотерапия. 2021;17(4):34–39. DOI: 10.33978/2307-3586-2021-17-4-34-39. [Matoshina I.V., Fedorin M.M., Livzan M.A., Mozgovoy S.I. Resistance of the Esophageal Mucosa in Patients with GERD: the Dialogue Between Clinician and Pathologist. Effektivnaya farmakoterapiya. 2021;17(4):34–39 (in Russ.)]. DOI: 10.33978/2307-3586-2021-17-4-34-39.
52. Palmieri B., Merighi A., Corbascio D. et al. Fixed combination of hyaluronic acid and chondroitin-sulphate oral formulation in a randomized double blind, placebo controlled study for the treatment of symptoms in patients with non-erosive gastroesophageal reflux. Eur Rev Med Pharmacol Sci. 2013;17(24):3272–3278. PMID: 24379055.
53. Savarino V., Pace F., Scarpignato C.; Esoxx Study Group. Randomised clinical trial: mucosal protection combined with acid suppression in the treatment of non-erosive reflux disease — efficacy of Esoxx, a hyaluronic acid-chondroitin sulphate based bioadhesive formulation. Aliment Pharmacol Ther. 2017;45(5):631–642. DOI: 10.1111/apt.13914.
54. Матошина И.В., Ливзан М.А., Федорин М.М., Лаптева И.В. Эффективность комбинированной терапии больных эрозивной гастроэзофагеальной рефлюксной болезнью. РМЖ. Медицинское обозрение. 2021;5(6):366–372. DOI: 10.32364/2587-6821-2021-5-6-366-372. [Matoshina I.V., Livzan M.A., Fedorin M.M., Lapteva I.V. Efficacy of combined therapy in patients with erosive gastroesophageal reflux disease. Russian Medical Inquiry. 2021;5(6):366–372 (in Russ.)]. DOI: 10.32364/2587-6821-2021-5-6-366-372.
55. Матошина И.В., Мозговой С.И., Ливзан М.А., Федорин М.М. Новые возможности терапии эрозивной формы гастроэзофагеальной рефлюксной болезни: собственные данные. Современные проблемы науки и образования. 2021;5:86. DOI: 10.17513/spno.31128. [Matoshina I.V., Mozgovoy S.I., Livzan M.A., Fedorin M.M. New therapy options for erosive gastroesophageal reflux disease: own data. Sovremennyye problemy nauki i obrazovaniya. 2021;(5):86 (in Russ.)]. DOI: 10.17513/spno.31128.
56. Chmielecka-Rutkowska J., Tomasik B., Pietruszewska W. The role of oral formulation of hyaluronic acid and chondroitin sulphate for the treatment of the patients with laryngopharyngeal reflux. Otolaryngol Pol. 2019;73(6):38–49. DOI: 10.5604/01.3001.0013.5776.
This work is licensed under a Creative Commons «Attribution» 4.0 License.
Previous article
Next article
